Dr. David Maloney is the Medical Director of Cellular Immunotherapy at Fred Hutchinson Cancer Research Center and Professor of Medicine at University of Washington’s oncology division, as well as a member of clinical research at the Fred Hutchinson Cancer Research Center. He received his medical degreee and doctorate in cancer biology from Stanford University, completed his internship and residency in internal medicine at Brigham and Woman’s Hospital, and a fellowship in oncology at Stanford. He joined Fred Hutchinson Cancer Research Center and the University of Washington in 1994.
He has authored and co-authored than 200 articles for publication in peer-reviewed journals in clinical research and oncology. In 1993, the International Society for Biology Therapy of Cancer (now the Society for Immunotherapy of Cancer) awarded him the Presidential Award. His care and commitment to patients is routinely acknowledged, most recently when Dr. Maloney was included in Newsweek’s Top Cancer Doctors 2015, the Castle Connolly Guide, America’s Top Doctors for Cancer 2016, and named by his peers as a Top Doctor in Medical Oncology 2017, Seattle Magazine.
For much of his career, Dr. Maloney has focused on developing and improving antibody-based therapies against blood cancers. He was instrumental in the development and testing of rituximab (Rituxan) while working with Dr. Ron Levy at Stanford.
Currently, his primary interests are in the development of chimeric antigen receptor (CAR) T-cell therapy for which he leads multiple clinical trials using this therapy for a variety of cancers.